[Click eStock] "Pharmaresearch, Overseas Sales Ratio ↑"

Daol Investment & Securities expected on the 8th that Pharmaresearch's corporate value could be re-evaluated due to its third-quarter performance and increased overseas sales this year.

Pharmaresearch recorded sales of 83.3 billion KRW and operating profit of 30.8 billion KRW in the second quarter of this year. These figures represent increases of 25% and 30%, respectively, compared to the same period last year.

Jonghyun Park, a researcher at Daol Investment & Securities, explained, "Improvement in performance was driven by cosmetics exports and domestic medical device sectors. Domestic medical devices increased by 12% year-on-year due to steady sales of Rejuran despite the launch of generic and competing products," he said.

He continued, "Cosmetics exports increased by 26% due to higher sales in offline stores in Japan and duty-free shops in Southeast Asia," adding, "pharmaceutical exports rose by 38% due to an increase in high-priced 200U toxin mix sales."

He stated, "The proportion of overseas sales reached 39%," and predicted, "the overseas sales ratio will surpass 40% for the first time in the third quarter." Additionally, he said, "This will resolve the low overseas sales ratio, which was a reason for Pharmaresearch's undervaluation," and raised the target stock price from 180,000 KRW to 220,000 KRW.